The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Intellia Therapeutics, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025
The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between July 30, 2024 and January 8, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2025.
The Lawsuit
The lawsuit against Intellia Therapeutics, Inc. alleges that the Company made materially false and/or misleading statements and failed to disclose material adverse facts. It is claimed that Intellia failed to disclose the true nature and extent of certain clinical results from its experimental gene editing treatment, leading to an artificially inflated share price.
Investors who suffered losses during the Class Period are encouraged to contact The Schall Law Firm for more information and to participate in the lawsuit.
How Will This Affect You?
If you are an investor who purchased Intellia Therapeutics, Inc. securities between July 30, 2024 and January 8, 2025, it is important to be aware of this class action lawsuit. By contacting The Schall Law Firm before April 14, 2025, you may be able to seek compensation for any losses suffered as a result of the alleged securities law violations.
How Will This Affect the World?
Class action lawsuits against companies for securities violations can have far-reaching effects on the world of finance. They serve to hold companies accountable for their actions and provide investors with a means of seeking justice for any losses incurred. In the case of Intellia Therapeutics, Inc., this lawsuit could potentially lead to changes in how the company discloses information and conducts its operations, as well as setting a precedent for similar cases in the future.
Conclusion
It is important for investors to stay informed on the progress of this class action lawsuit against Intellia Therapeutics, Inc. and to take appropriate action if they have been affected. By seeking legal counsel and participating in the lawsuit, investors may be able to recover losses and hold the company accountable for any alleged securities violations.
